RecruitingPhase 2NCT07512700
Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia
Studying Acute monoblastic/monocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chinese PLA General Hospital
- Principal Investigator
- Liping Dou, DoctorChinese PLA General Hospital
- Intervention
- CACAG+VEN(drug)
- Enrollment
- 204 target
- Eligibility
- 14-60 years · All sexes
- Timeline
- 2025 – 2029
Study locations (3)
- Air Force Medical Center, PLA, Beijing, China
- Chinese PLA General Hospital, Beijing, China
- PLA Strategic Support Force's Characteristic Medical Center, Beijing, China
Collaborators
Air Force Medical Center of PLA · PLA Strategic Support Force's Characteristic Medical Center
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07512700 on ClinicalTrials.govOther trials for Acute monoblastic/monocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06504459Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLOHSU Knight Cancer Institute
- RECRUITINGPHASE1NCT06429449Mitoxantrone for Venetoclax Resistant Acute Myeloid LeukemiaUniversity of Colorado, Denver
- ACTIVE NOT RECRUITINGNANCT05871008Integrated Actionable Aging Assessment for Cancer Patients PilotUniversity of Colorado, Denver
- RECRUITINGPHASE2NCT05566054Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic LeukemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT04282187Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsUniversity of Washington
- ACTIVE NOT RECRUITINGPHASE2NCT04195945CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit PatientsFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT03737955Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid LeukemiaUniversity of Washington